Send to

Choose Destination
AIDS Res Hum Retroviruses. 2018 Aug 15. doi: 10.1089/AID.2018.0142. [Epub ahead of print]

Baseline Investigation of HIV-1 Primary Drug Resistance Among Newly Diagnosed Treatment-Naïve HIV-1 Individuals in Hebei, China.

Author information

1 Hebei Provincial Center for Disease Control and Prevention , Shijiazhuang, China .
2 College of Public and Health, Hebei Medical University , Shijiazhuang, China .


Human immunodeficiency virus (HIV) primary drug resistance (PDR) has influenced the long-term therapeutic effects of antiretroviral drugs. However, for the overall PDR prevalence in China, no report was found in published articles. In our study, an extensive cross-sectional investigation based on all newly diagnosed treatment-naive HIV-infected individuals was conducted. The overall prevalence of HIV-1 PDR among newly diagnosed treatment-naive HIV-1 individuals was 8.3% (60/720), obviously beyond the warning line (5.0%) set by WHO. The prevalence of PDR to PIs, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors was 4.9% (35/720), 0.4% (3/720), and 2.5% (18/720), respectively. Moreover, the occurrence of HIV-1 PDR strains was random among different prefectures. HIV-1 PDR strains were extensively circulating among the sexual contact population inside and outside the Hebei province, especially between neighboring provinces and Hebei. Hebei province has become the moderate level PDR epidemic area. Enhanced surveillance for PDR is necessary among treatment-naïve individuals in Hebei, and we must take effective measures to cut off the spread of HIV PDR strains.


HIV-1; MSM; phylogenetic analysis; primary drug resistance


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center